Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial Results for the First Half of 2022 Copenhagen, DK...
NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”)EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS (“ADRs”)REPRESENTING DEPOSITED ORDINARY SHARES...
Company announcement – No. 32 / 2022 Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select...
Company announcement – No. 31 / 2022 Zealand Pharma Hosts Conference Call on August 11 at 4 pm CET (10am ET) to Present Second Quarter Results for...
Company announcement – No. 30 / 2022 Total number of shares and voting rights in Zealand Pharma at June 30, 2022 Copenhagen, DK and Boston, MA, June 30,...
Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company...
Company announcement – No. 29 / 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities Copenhagen, DK and...
Company announcement – No. 28 / 2022 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 Copenhagen, DK and Boston, MA, 10 June...
COMPANY ANNOUNCEMENT – NO. 27/ 2022 Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association...
Company announcement – No. 26 / 2022 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR...